Could a homeopathic remedy ease cancer treatment fatigue?
NCT ID NCT07707648
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a questionnaire and a smartwatch. The trial is small and early-stage, focusing on safety and feasibility.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- a homeopathic combination product called Encer, made from five homeopathic ingredients
- What this could lead to
- If it works, this could offer a low-risk option to help cancer patients feel less tired during treatment.
- What could go wrong
- This is a very early feasibility study with only 74 participants, and homeopathy's effects are often debated. The trial may not show a clear benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 74 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2025
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subject's informed consent 2. Either male or female 3. Age 18 and above 4. Diagnosed with cancer (any type of solid tumor) 5. Patients planned for their initial treatment or a new regimen of chemotherapy, (at least 4 treatments planned within 12 weeks) a new regimen of radiotherapy (at least 15 fractions planned) 6. Able to interface with digital questionnaire sent to the patient electronically 7. Willing to wear a smartwatch that will detect physiological measurements for the duration of the trial 8. Not currently treated with homeopathic remedy (for at least one week prior to study treatment) Exclusion Criteria: 1. Unable to give informed consent 2. Planned Radiotherapy for less than 15 fractions 3. Chemotherapy anticipated for less than 12 weeks, or fewer than 4 treatments 4. Life expectancy of less than 3 months 5. Patient is a dependent of the sponsor, of the investigational team or his/her immediate family 6. Pregnant or nursing women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Fatigue related to cancer treatment are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Assuta Medical Centers Ramat HaHayal
RECRUITINGTel Aviv, 6971032, Israel
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- First human test of BI 4060107 aims to find safe dose for Hard-to-Treat tumors
- Can a new drug shield kidneys from chemotherapy damage?
- Mining Responders' tumors for clues to a universal cancer therapy
- Proton boost radiotherapy aims to hit large tumors harder while sparing healthy tissue
- New antibody aims to preserve immune checkpoint while fighting cancer
- Engineered immune cells target two markers on Hard-to-Treat tumors